Theravance (THRX) Halted For Trading Ahead of FDA Meeting
More News related to THRX
- Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
- Theravance to Present at the 18th Annual Credit Suisse Health Care Conference
- Theravance Announces New Employment Inducement Award
- Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe
- Theravance (THRX) Posts Q3 Loss of $0.35; Revs Light
More News related to FDA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
Theravance, Inc. (Nasdaq: THRX) announced that NASDAQ halted trading of Theravance common stock this morning, November 19, 2008.
The Anti-Infective Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) meets today to review and discuss the company's New Drug Application (NDA) for telavancin, a novel, bactericidal, once-daily injectable investigational antibiotic for the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA).
Related Categories
FDAStocks Mentioned
+0.15Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
